Is Berkshire Hathaway Being Too Patient With Its Cash?

Core Insights - Berkshire Hathaway reported a cash balance of $373.3 billion at the end of Q4, down from $381.6 billion in Q3, after spending $9.7 billion on the acquisition of OxyChem [2] - The company has been a net seller of stocks for 13 consecutive quarters, primarily selling shares of Apple and Bank of America, while maintaining Apple as its largest holding [4] - Berkshire has not repurchased any of its own shares for six straight quarters, although it recently initiated buybacks [5] Financial Performance - The market capitalization of Berkshire Hathaway is currently $1.1 trillion, with a stock price around $497.20 [9] - The stock is trading at approximately 1.4 times book value, down from a peak of 1.8 times, indicating a more favorable valuation compared to historical levels [6] Management Strategy - New CEO Greg Abel emphasized the need for patience with the company's cash reserves and highlighted the importance of risk management beyond its insurance businesses [7] - Investors are expressing frustration over the company's lack of action, particularly in the context of technological advancements, which Berkshire has not capitalized on [9] Investment Outlook - There is a belief that Berkshire Hathaway represents a good long-term investment as its stock valuation approaches more attractive levels, especially with the recent buyback activity [10]